WG
CYTK icon

Winton Group’s Cytokinetics CYTK Stock Holding History

Winton Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$774K Buy
+9,088
New +$653K 0.03% 572
2025
Q3 		– Sell
-28,159
Closed -$930K – 791
2025
Q2 		$930K Buy
28,159
+3,904
+16% +$136K 0.05% 453
2025
Q1 		$975K Buy
24,255
+5,250
+28% +$241K 0.06% 432
2024
Q4 		$894K Buy
19,005
+9,210
+94% +$478K 0.06% 372
2024
Q3 		$517K Sell
9,795
-8,354
-46% -$466K 0.04% 438
2024
Q2 		$983K Buy
+18,149
New +$1.1M 0.07% 250
2024
Q1 		– Sell
-17,596
Closed -$1.47M – 663
2023
Q4 		$1.47M Buy
+17,596
New +$637K 0.11% 145
2023
Q2 		– Sell
-11,380
Closed -$400K – 850
2023
Q1 		$400K Buy
11,380
+1,000
+10% +$40.8K 0.02% 757
2022
Q4 		$476K Buy
10,380
+3,403
+49% +$146K 0.03% 648
2022
Q3 		$338K Sell
6,977
-297
-4% -$14.3K 0.02% 757
2022
Q2 		$286K Buy
+7,274
New +$293K 0.02% 815
2022
Q1 		– Sell
-6,868
Closed -$313K – 995
2021
Q4 		$313K Buy
+6,868
New +$265K 0.02% 816

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winton Group's CYTK Position: Q2 2026 in Review

Winton Group opened a new position in Cytokinetics (CYTK) in Q2 2026: 9,088 shares worth $774K. The stake represents 0.03% of the portfolio and ranks #572 among its holdings. This is a return to the name: Winton Group previously reported a position in CYTK as recently as Q2 2025.

Winton Group first reported a position in CYTK in Q4 2021 and has held it in 12 quarters since. The position peaked at $1.47M in Q4 2023. 484 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Winton Group held 9,088 shares of Cytokinetics worth $774K as of Q2 2026.
  • Cytokinetics was a new Winton Group position in Q2 2026.
  • Cytokinetics made up 0.03% of Winton Group's portfolio in Q2 2026, its #572 holding.
  • Winton Group first reported a position in Cytokinetics in Q4 2021 and has held it in 12 quarters since.
  • Winton Group's Cytokinetics position peaked at $1.47M in Q4 2023.
  • 484 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.